This week's roundup of Houston innovators includes Sunny Zhang of TrueLeap, Jim Dillon of BiVACOR, and Livia Schiavinato Eberlin of Baylor College of Medicine. Photos courtesy

Editor's note: Each week, I'm introducing you to three Houston innovators to know — three individuals behind recent innovation and startup news stories in Houston as reported by InnovationMap. Learn more about them and their recent news below by clicking on each article.

Sunny Zhang, founder of TrueLeap

Sunny Zhang joins the Houston Innovators Podcast. Photo via LinkedIn

It's safe to say Sunny Zhang has a handle on the machine and cycle that innovation as a tenured business professor, startup founder, and venture capital investor. An academic at her core, she looks at innovation from the outside in — and inside out — in her various roles.

But there is a throughline for Zhang, and it's observing the innovation cycle. In her 20 years, she's worked closely with startups on the topic.

"My research has always focused on the innovation diffusion process — essentially the psychological and behavioral science of innovation diffusion when a product is introduced in a marketplace. How is that adoption going in a network as a result in many factors — internally and externally in a digital world and in the international and global market," Zhang says on the Houston Innovators Podcast.

"I've been seeing how innovation works, how products are getting adopted, and the behavioral process in it. We talk about 'go-to market,' but I want to promote 'come-from market.' Identify the problem itself," Zhang says, explaining that as both an academic and life-long learner, this is important to her.

Jim Dillon, CEO of BiVACOR

Jim Dillon has been named CEO of BiVACOR. Photo courtesy of BiVACOR

Houston-based medical device company BiVACOR has brought aboard a new CEO.

Jim Dillon, a longtime executive in the medical device sector, has been hired to lead BiVACOR and join its board of directors. Dillon succeeds former heart surgeon Dr. Thomas Vassiliades, whose appointment as CEO was announced in January 2022.

“Jim’s leadership style, combined with his experience in building high-performance teams as well as expertise in the heart failure field, makes him the ideal person to lead BiVACOR,” Raymond Cohen, chairman of BiVACOR, says in a news release. Continue reading.

Livia Schiavinato Eberlin, associate professor of surgery at Baylor College of Medicine

Livia Schiavinato Eberlin was named the 2024 recipient of the Norman Hackerman Award in Chemical Research. Photo via bcm.edu

An associate professor of surgery at Baylor College of Medicine has won a prestigious award for young chemical scientists in the state and secured $3 million in funding to further develop her technology.

Livia Schiavinato Eberlin was named the 2024 recipient of the Norman Hackerman Award in Chemical Research in December. The award was established by the Houston-based Welch Foundation and recognizes the accomplishments of chemical scientists in Texas who are early in their careers. Eberlin will be granted $100,000 for this honor.

Eberlin runs the Eberlin Lab for Medical Mass Spectrometry at BCM and is known for her groundbreaking work in the application of mass spectrometry technologies, which are changing how physicians treat cancer and analyze tissues.

In the same week, Baylor College of Medicine announced that the Eberlin Lab received $3 million in funding from The Marcus Foundation to further develop the MasSpec Pen technology in breast cancer surgeries. Eberlin developed the tool in 2016 while she was serving as an assistant professor at the University of Texas at Austin. The MasSpec Pen is a device for detecting cancer directly on tissues. Continue reading.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston cleantech, space startups named to World Economic Forum cohort

top honor

Two Houston-based startups have been selected to join the World Economic Forum's Technology Pioneers community.

The two-year program aims to help mission-driven, early-stage start-ups scale their innovations through multi-stakeholder initiatives, co-creating partnerships and other gatherings for community members. One-hundred startups are selected each year from around the globe, this year hailing from 23 countries and working in AI, energy, space, biotech markets and more.

Cleantech startup Vaulted Deep was one of 11 energy and climate companies to be named to the cohort. Julia Reichelstein and Omar Abou-Sayed founded the company in 2023. Its technology injects excess organic waste underground to remove carbon dioxide from the atmosphere.

Last year, Vaulted Deep inked a 12-year deal with Microsoft to remove up to 4.9 million metric tons of carbon dioxide from the environment.

The startup has earned several accolades in recent years, including a No. 3 spot on Fast Company’s list of the World’s Most Innovative Companies of 2026. It was also recently named to market intelligence and advisory firm Cleantech Group's annual Global Cleantech 100 list for a second year in a row.

"Waste management is one of the world's great invisible infrastructure systems ... The need for new infrastructure is growing as disposal challenges become more complex and regulations evolve. Vaulted is building the first new disposal pathway for organic waste in decades by putting it deep underground, permanently," the company shared in a LinkedIn post. "This year, we're joining the World Economic Forum's 2026 Tech Pioneers alongside innovators working on the many interconnected challenges shaping our future."

Houston-based Venus Aerospace was also selected to join the cohort, along with six other spacetech companies. The company was founded in 2020 by Sassie and Andrew Duggleby.

The startup specializes in next-generation rocket engine propulsion as a cleaner alternative to traditional combustion engines. The company's rotating detonation rocket engine (RDRE) burns fuel more efficiently and completed a successful high-thrust test flight last year. Venus says it’s the only company in the world that makes a flight-proven, high-thrust RDRE with a “clear path to scaled production.”

"Frontier technologies matter most when they expand what people, industries, and nations can do," Sassie Duggleby, co-founder and CEO of Venus, said in a news release. "For Venus, RDRE does not just represent a more efficient engine. It is a foundation for faster movement, more capable space systems, and new forms of connectivity across the planet. Being named a Technology Pioneer validates the potential of this technology to help shape a future where distance is less limiting."

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston Methodist receives record $110M gift, names future tower

historic gift

Houston Methodist has received the largest gift in the health system's history to establish new funds for neurological, neuroscience, and women’s health research and treatment.

The $110 million gift comes from Houston-based The Brockman Medical Research Foundation, which supports education and research in the science, medicine and healthcare fields. In response, Houston Methodist announced that it will name its forthcoming 26-story hospital facility the Brockman Centennial Tower.

The tower’s entrance will be named the Anna Margaret Bellows Centennial Hall to honor Anna Margaret Bellows, a young camper who died during the Camp Mystic flooding last summer.

“This extraordinary gift accelerates discovery and transforms how care is delivered,” Dr. Marc Boom, president and CEO of Houston Methodist, said in a news release. “We are grateful to The Brockman Medical Research Foundation for its incredible generosity and vision that will help change the lives of generations of patients. Naming Centennial Tower in recognition of this gift reflects the scale of this commitment and its impact on the future of neuroscience, neurological care and women’s health.”

The gift will be divided into two parts:

  • $100 million will go toward creating an innovation fund within the Houston Methodist Academic Institute and the Houston Methodist Neurological Institute
  • $10 million will be devoted to Houston Methodist's Department of Obstetrics and Gynecology

“This tremendous gift will accelerate translational research that broadens our understanding of neurological and other diseases,” Dr. Jenny Chang, president and CEO of the Houston Methodist Academic Institute, added in the release. “It will allow us to leverage state-of-the-art platforms to detect, diagnose and deliver therapeutics, keeping patient care at the center of our mission.”

The Brockman Centennial Tower is expected to open next year in the Texas Medical Center. Spanning more than 1 million square feet, it will house 400 patient beds, an expanded emergency department, new operating rooms and a rooftop garden. It will be connected to Houston Methodist's flagship Paula and Joseph C. “Rusty” Walter III Tower, which opened in 2018. The Centennial Tower was estimated to cost $1.4 billion when announced in 2022.

In addition to the news of the Brockman gift, Houston Methodist also announced this month that it has launched the Houston Methodist Center for Cell and Gene Therapy and tapped an internationally recognized scientist as its leader.

The new center is focused on discovering and developing innovative and cost-effective therapies for a variety of congenital and acquired diseases, including cancer, HIV and cardiovascular disease.

Dr. Malcolm Brenner has been named as the center's inaugural leader and will assume the role starting in October. He will work alongside scientists and support staff from Baylor College of Medicine and Texas Children's Hospital.

Brenner is a professor of pediatrics, medicine, molecular and human genetics and translational biology at Baylor College of Medicine. He is known for making early advances in using bone marrow transplantation as a form of cell therapy and in engineered immune-cell treatments for cancer and infections, according to a release from Houston Methodist.

“Malcolm Brenner is a pioneer in the field of cell and gene therapy and is uniquely qualified to lead Houston Methodist’s research efforts in this field,” Chang added. “His vision and leadership will play a pivotal role in advancing our work in this space.”